AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 8061.9
(2.24%)
INR 8061.9
(2.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.35 Billion INR | -2.28% |
| 2022 | 1.5 Billion INR | 91.81% |
| 2021 | 1 Billion INR | -32.66% |
| 2020 | 1.47 Billion INR | 9.55% |
| 2019 | 1.33 Billion INR | 52.4% |
| 2018 | 875.9 Million INR | 71.33% |
| 2017 | 488.6 Million INR | 12.31% |
| 2016 | 454.5 Million INR | 172.43% |
| 2015 | 167.39 Million INR | 450.27% |
| 2014 | -55.58 Million INR | 83.62% |
| 2013 | -291 Million INR | 60.13% |
| 2012 | -729.95 Million INR | -337.47% |
| 2011 | 307.38 Million INR | -70.57% |
| 2010 | 1.04 Billion INR | 9.12% |
| 2009 | 942.54 Million INR | -24.29% |
| 2008 | 1.24 Billion INR | 25.35% |
| 2007 | 998.53 Million INR | 32.57% |
| 2006 | 760.74 Million INR | 8.72% |
| 2005 | 699.7 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 380.7 Million INR | -119.17% |
| 2023 Q2 | 611.32 Million INR | -18.87% |
| 2023 Q1 | 753.49 Million INR | 172.92% |
| 2023 Q4 | 493.88 Million INR | 99.82% |
| 2023 Q3 | 247.16 Million INR | -59.57% |
| 2023 FY | - INR | -2.28% |
| 2022 Q3 | 437.85 Million INR | -7.86% |
| 2022 Q4 | 276.08 Million INR | -36.94% |
| 2022 Q1 | 320.79 Million INR | -18.0% |
| 2022 Q2 | 475.18 Million INR | 48.13% |
| 2022 FY | - INR | 91.81% |
| 2021 Q3 | 199.97 Million INR | -3.67% |
| 2021 Q4 | 391.22 Million INR | 95.64% |
| 2021 FY | - INR | -32.66% |
| 2021 Q1 | 185.3 Million INR | -56.47% |
| 2021 Q2 | 207.59 Million INR | 12.03% |
| 2020 Q2 | 404.68 Million INR | 29.62% |
| 2020 FY | - INR | 9.55% |
| 2020 Q4 | 425.69 Million INR | 26.43% |
| 2020 Q3 | 336.71 Million INR | -16.8% |
| 2020 Q1 | 312.19 Million INR | 74.39% |
| 2019 Q1 | 385.51 Million INR | 1074.69% |
| 2019 Q2 | 367.2 Million INR | -4.75% |
| 2019 Q3 | 402.25 Million INR | 9.54% |
| 2019 Q4 | 179.02 Million INR | -55.49% |
| 2019 FY | - INR | 52.4% |
| 2018 FY | - INR | 71.33% |
| 2018 Q3 | 443.75 Million INR | 144.93% |
| 2018 Q4 | -39.55 Million INR | -108.91% |
| 2018 Q1 | 127.02 Million INR | -27.86% |
| 2018 Q2 | 181.17 Million INR | 42.63% |
| 2017 Q4 | 176.07 Million INR | 317.75% |
| 2017 Q3 | -80.86 Million INR | -121.2% |
| 2017 Q2 | 381.45 Million INR | 250.89% |
| 2017 Q1 | 108.71 Million INR | 544.67% |
| 2017 FY | - INR | 12.31% |
| 2016 Q2 | 50.55 Million INR | -74.16% |
| 2016 Q4 | 16.86 Million INR | -93.26% |
| 2016 Q3 | 250.21 Million INR | 394.91% |
| 2016 FY | - INR | 172.43% |
| 2016 Q1 | 195.66 Million INR | 1740.02% |
| 2015 FY | - INR | 450.27% |
| 2015 Q4 | -11.93 Million INR | -109.09% |
| 2015 Q3 | 131.18 Million INR | 688.87% |
| 2015 Q2 | -22.27 Million INR | -131.83% |
| 2015 Q1 | 70 Million INR | -83.71% |
| 2014 Q4 | 429.73 Million INR | 575.67% |
| 2014 FY | - INR | 83.62% |
| 2014 Q1 | -141.71 Million INR | 63.5% |
| 2014 Q2 | -245.01 Million INR | -72.9% |
| 2014 Q3 | -90.34 Million INR | 63.13% |
| 2013 Q4 | -388.2 Million INR | -953.46% |
| 2013 FY | - INR | 60.13% |
| 2013 Q1 | 35.44 Million INR | 112.62% |
| 2013 Q2 | 16.27 Million INR | -54.08% |
| 2013 Q3 | 45.48 Million INR | 179.5% |
| 2012 Q3 | -151.55 Million INR | 17.24% |
| 2012 Q2 | -183.13 Million INR | -60.19% |
| 2012 Q1 | -114.32 Million INR | 78.37% |
| 2012 FY | - INR | -337.47% |
| 2012 Q4 | -280.94 Million INR | -85.38% |
| 2011 Q4 | -528.53 Million INR | -321.26% |
| 2011 Q3 | 238.87 Million INR | 0.0% |
| 2011 FY | - INR | -70.57% |
| 2010 FY | - INR | 9.12% |
| 2009 FY | - INR | -24.29% |
| 2008 FY | - INR | 25.35% |
| 2007 FY | - INR | 32.57% |
| 2006 FY | - INR | 8.72% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 75.493% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 96.186% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 65.659% |
| Granules India Limited | 8.6 Billion INR | 72.608% |
| Indoco Remedies Limited | 2.64 Billion INR | 10.965% |
| Achyut Healthcare Limited | 524 Thousand INR | -449670.992% |
| Ajanta Pharma Limited | 12.56 Billion INR | 81.244% |
| Alkem Laboratories Limited | 24.19 Billion INR | 90.259% |
| Alpa Laboratories Limited | 86.12 Million INR | -2636.424% |
| Brooks Laboratories Limited | 41.72 Million INR | -5548.006% |
| Bajaj HealthCare Limited | 444.51 Million INR | -430.195% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -59.348% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 97.33% |
| Eris Lifesciences Limited | 6.98 Billion INR | 66.266% |
| FDC Limited | 4.4 Billion INR | 46.457% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 79.224% |
| Gufic Biosciences Limited | 1.48 Billion INR | -59.191% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 65.653% |
| Ipca Laboratories Limited | 13.29 Billion INR | 82.279% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -628.622% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 2948.889% |
| Lasa Supergenerics Limited | -65.08 Million INR | 3721.389% |
| Laurus Labs Limited | 8 Billion INR | 70.562% |
| Lupin Limited | 36.96 Billion INR | 93.625% |
| Mankind Pharma Limited | 28.09 Billion INR | 91.611% |
| Medicamen Biotech Limited | 245.66 Million INR | -859.375% |
| Medico Remedies Limited | 150.37 Million INR | -1467.251% |
| Megasoft Limited | 284.73 Million INR | -727.729% |
| NATCO Pharma Limited | 18.79 Billion INR | 87.46% |
| Piramal Pharma Limited | 13.05 Billion INR | 81.948% |
| RPG Life Sciences Limited | 1.28 Billion INR | -83.909% |
| Sigachi Industries Limited | 883.39 Million INR | -166.788% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.297% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 49.611% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -447.741% |
| Unichem Laboratories Limited | 742.35 Million INR | -217.476% |
| Wanbury Limited | 985.49 Million INR | -139.15% |
| Windlas Biotech Limited | 781.72 Million INR | -201.489% |
| ZIM Laboratories Limited | 462.09 Million INR | -410.023% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 95.808% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 163.164% |
| Divi's Laboratories Limited | 25.43 Billion INR | 90.732% |
| Hester Biosciences Limited | 539.47 Million INR | -336.873% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 21.815% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -245.299% |
| Bal Pharma Limited | 345.59 Million INR | -581.96% |
| Strides Pharma Science Limited | 3.76 Billion INR | 37.397% |
| Venus Remedies Limited | 711.8 Million INR | -231.104% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 39.715% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -50.711% |
| Shilpa Medicare Limited | 2.58 Billion INR | 8.933% |
| Aarti Drugs Limited | 3.24 Billion INR | 27.452% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 9.583% |
| Suven Life Sciences Limited | -992.78 Million INR | 337.394% |
| Ind-Swift Limited | 1.06 Billion INR | -121.282% |
| Valiant Laboratories Limited | 12.73 Million INR | -18400.667% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 74.753% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 183.518% |
| Themis Medicare Limited | 562.6 Million INR | -318.907% |
| Hikal Limited | 2.69 Billion INR | 12.459% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 93.268% |
| Sequent Scientific Limited | 549.8 Million INR | -328.665% |
| Novartis India Limited | 1.26 Billion INR | -85.677% |
| Wockhardt Limited | 1.08 Billion INR | -118.222% |
| Jubilant Pharmova Limited | 8 Billion INR | 70.562% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -17943.179% |
| Neuland Laboratories Limited | 4.74 Billion INR | 50.364% |
| Morepen Laboratories Limited | 1.72 Billion INR | -36.551% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -719.97% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -1247.159% |